Utah Medical Products (UTMD) EBITDA (2010 - 2026)

Utah Medical Products' EBITDA history runs 17 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• In Q1 2026, EBITDA fell 44.11% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $12.1 million (down 7.18% YoY), while the FY2025 annual figure was $13.8 million, up 9.13% from the prior year.
• EBITDA was $2.1 million for Q1 2026 at Utah Medical Products, down from $2.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $6.9 million in Q4 2022 to a low of $884000.0 in Q4 2024.
• Historically, EBITDA has averaged $3.5 million across 5 years, with a median of $3.3 million in 2024.
• The sharpest annual moves came in 2024 and 2025: EBITDA sank 84.29% in 2024, then surged 226.7% in 2025.
• A 5-year view of EBITDA shows it stood at $6.9 million in 2022, then slipped by 19.0% to $5.6 million in 2023, then tumbled by 84.29% to $884000.0 in 2024, then soared by 226.7% to $2.9 million in 2025, then dropped by 27.25% to $2.1 million in 2026.
• The last three EBITDA figures came in at $2.1 million (Q1 2026), $2.9 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.